Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

+0.31 (+1.04%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
201,715 shs
Average Volume
379,377 shs
Market Capitalization
$1.66 billion
P/E Ratio
Dividend Yield
Price Target

Supernus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
35.5% Upside
$41.00 Price Target
Short Interest
9.20% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.30mentions of Supernus Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.23 M Sold Last Quarter
Proj. Earnings Growth
From $1.16 to $1.47 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

200th out of 909 stocks

Pharmaceutical Preparations Industry

80th out of 423 stocks

SUPN stock logo

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

SUPN Stock Price History

SUPN Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
Supernus Provides Regulatory Update for SPN-830
SUPN Apr 2024 29.000 call
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
See More Headlines
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$1.32 million
Pretax Margin


Sales & Book Value

Annual Sales
$607.52 million
Cash Flow
$1.61 per share
Book Value
$16.87 per share


Free Float
Market Cap
$1.66 billion
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Jack A. Khattar (Age 63)
    Founder, President, CEO, Secretary & Director
    Comp: $1.63M
  • Mr. Timothy C. Dec (Age 65)
    Senior VP & CFO
    Comp: $635.43k
  • Dr. Padmanabh P. Bhatt Ph.D. (Age 67)
    Chief Scientific Officer & Senior VP of Intellectual Property
    Comp: $594.14k
  • Mr. Frank Mottola (Age 52)
    Senior Vice President of Quality, GMP Operations & Information Technology
    Comp: $490.87k
  • Dr. Jonathan Rubin M.D. (Age 63)
    MBA, Senior VP of Research & Development and Chief Medical Officer
    Comp: $594.65k
  • Mr. Kevin T. Anderson (Age 62)
    Compliance Officer
  • Dr. Todd Horich M.B.A.
    Ph.D., Senior Vice President of Marketing & Market Access
  • Mr. Taylor Raiford
    Senior Vice President of Sales
  • Dr. Bryan A. Roecklein Ph.D.
    Senior Vice President of Corporate Development
  • Ms. Tami T. Martin Esq. (Age 69)
    R.N., Senior Vice President of Regulatory Affairs
    Comp: $508.5k

SUPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings
or view top-rated stocks.

What is Supernus Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12-month target prices for Supernus Pharmaceuticals' shares. Their SUPN share price targets range from $41.00 to $41.00. On average, they predict the company's share price to reach $41.00 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for SUPN
or view top-rated stocks among Wall Street analysts.

How have SUPN shares performed in 2024?

Supernus Pharmaceuticals' stock was trading at $28.94 on January 1st, 2024. Since then, SUPN shares have increased by 4.6% and is now trading at $30.26.
View the best growth stocks for 2024 here

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SUPN earnings forecast

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.41 by $0.39. The specialty pharmaceutical company had revenue of $164.30 million for the quarter, compared to the consensus estimate of $155.03 million. Supernus Pharmaceuticals had a net margin of 0.22% and a trailing twelve-month return on equity of 0.14%. The business's quarterly revenue was down 1.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 earnings per share.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $580.0 million-$620.0 million, compared to the consensus revenue estimate of $622.5 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (1.89%), Rice Hall James & Associates LLC (0.94%), Tributary Capital Management LLC (0.63%), Congress Wealth Management LLC DE (0.32%), Bridge City Capital LLC (0.15%) and Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Frank Mottola, Frederick M Hudson, Jack A Khattar, Padmanabh P Bhatt and Tami Tillotson Martin.
View institutional ownership trends

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SUPN) was last updated on 4/24/2024 by Staff

From Our Partners